Fundraising FoxBasel · Seed–Growth · 7 people tracked
Find your way into Roche Venture Fund
Sign up to see every warm intro you have to Roche Venture Fund
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Roche Venture Fund team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
Source: firm website, verified Jul 29, 2026.
Team · 7 people
from the firm's website & curated & public directories
What they invest in
from 35 of 41 portfolio companiesBiotech ×32Healthtech ×21Medical Devices ×8Deep Tech ×6Digital Health ×4Enterprise Software ×2SaaS ×2AI & Machine Learning ×1
HQs:United States×23Spain×2France×2Switzerland×1Denmark×1Italy×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×22 founders×33 founders×24+ founders×1
Investments · 41 tracked
founders shown can be your intro pathBy year:2025 · 12022 · 12021 · 52020 · 12019 · 12018 · 22017 · 12016 · 32015 · 32014 · 22009 · 121 dated
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsARCH Venture PartnersBay City CapitalJanus Henderson Investors+2 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesAgent CapitalMPM BioImpactMRL Ventures FundTCG CrossoverWellington Management
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude Capital+4 more
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalLumira VenturesAngelini VenturesJDRF T1D Fund
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)inPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund
Komed Health provides a secure, real-time communication platform designed for hospitals to enhance collaboration among care teams and improve patient care delivery.
Digital HealthEnterprise SoftwareHealthtechSaaSZurich, CH
Marc(Technical Co-founder)
Co-investorsSICTIC
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)David Allison(Director)inKeno Gutierrez(Director)in
Co-investors5AM VenturesNovartis Venture FundVersant VenturesBioGeneration VenturesWestlake Village BioPartners
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsAsabys PartnersNovartis Venture FundSanofi VenturesYsios CapitalCriteria Bio VenturesNew Enterprise Associates (NEA)+3 more
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsHealthCapKurma PartnersNovartis Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more
BiotechWatertown, US
Edward Mascioli(Executive Officer)Andrew Myers(Director)
BoardMarkus Goebel(Director)Henry Skinner(Director)inVikas Goyal(Director)Raj Parekh(Director)in
Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018
Co-investorsAdvent Life SciencesGurnet Point CapitalNovartis Venture Fund
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)inBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)inJulian Symons(Executive Vice President, Chief Scientific Officer)in
Co-investorsPivotal Life SciencesWellington ManagementVivo Capital
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersLifeSci Venture PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapital
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRiverVest Venture PartnersSR One Capital Management
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in
Co-investorsRiverVest Venture PartnersVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersAbbVieJDRF T1D Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundSamsara BioCapitalTaiho Ventures, LLC+4 more
Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).
BiotechHealthtechMedical Devices
John
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRiverVest Venture Partners3x5 PartnersCodon Capital
The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalScottish National Investment BankSofinnova Partners
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)inYi Liu, Ph.D.(CEO)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalOrbiMed
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsSanofi VenturesAtlas VentureHatteras Venture PartnersLilly VenturesOmega Funds
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersYsios Capital+5 more
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)in
Co-investorsBioGeneration VenturesEpidarex CapitalSofinnova PartnersScottish National Investment Bank
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsRosetta Capital Ltd.Sofinnova PartnersSR One Capital ManagementIP Group
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsInkefLundbeckfonden Ventures
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsAvoro Capital Advisors
Co-investorsLifeforce CapitalPfizer Venture InvestmentsDigitalis VenturesLightstone VenturesMorgenthalerSR One Capital Management
Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.
CybersecurityEnterprise SoftwareSaaSCharleston, US
Glenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)
Co-investorsCheckmate Capital Group LLC5AM Ventures
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Quan CapitalVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alios BiopharmaAveXisCiVi BiopharmaEntradaMergeTheraPalladio BiosciencesPurigen Biosystems, Inc.Receptive BioVasculox
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
4 IPOs · 1 acquisitionsEnliven TherapeuticsNASDAQ: ELVNEntrada Therapeutics, Inc.NASDAQ: TRDAFreenomeNASDAQ: FRNMSUTROVAX, INC.NASDAQ: PCVXGood Therapeuticsacq. by Roche
Portfolio news
latest coverage across their companiesMironid · eu-startups.com · Aug 7, 2026
Mission Therapeutics · finsmes.com · Oct 15, 2025
Bonum Therapeutics · biospace.com · Jun 10, 2025
Frequently asked questions
- How many investments has Roche Venture Fund made?
- Roche Venture Fund has 41 tracked investments, 5 of which have exited, including 1 dated in the last 24 months.
- What stage does Roche Venture Fund invest at?
- Roche Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Roche Venture Fund's typical check size?
- Roche Venture Fund typically writes checks of $648K – $3.2M.
- What sectors does Roche Venture Fund focus on?
- Roche Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices, Sector Agnostic.
- Where is Roche Venture Fund located?
- Roche Venture Fund is headquartered in Basel, CH.
- Who does Roche Venture Fund co-invest with?
- Roche Venture Fund most often shares deals with Sofinnova Partners, Novartis Venture Fund, Pfizer Venture Investments, among 66 tracked co-investors.
Media · Podcasts & interviews
featuring the team#OptimumTV with Anja Harmeier of Roche Venture Fund for #lifescience investor outlook on 2026
Optimum Strategic Communications · Anja Harmeier
Images
Co-investors · 23
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Novartis Venture Fund invests in innovative life science companies, primarily in biotechnology and biopharmaceuticals, at various stages of development across North America and Europe.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.
BioGeneration Ventures is a European venture capital firm investing in early-stage biotech, medtech and life sciences companies developing novel therapeutics and medical technologies.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Inkef Capital is an early-stage, hands-on investor that partners with founders to build companies with a long-term strategic vision.
▶11 more co-investors
Novo HoldingsCodon CapitalAtlas VentureDeerfield Management CompanyMorgenthalerHatteras Venture PartnersOmega FundsLightstone VenturesFaberWestlake Village BioPartnersApollo Health Ventures
Firms observed investing alongside Roche Venture Fund, from public investor directories. Shared companies are the overlap with Roche Venture Fund's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.